	US 12,263,165 B2
	Small molecule inhibitors of cancer stem cells and mesenchymal cancer types
Luke L. Lairson, San Diego, CA (US); Michael J. Bollong, San Diego, CA (US); Peter G. Schultz, La Jolla, CA (US); and Sendurai A. Mani, Houston, TX (US)
Assigned to The Scripps Research Institute, La Jolla, CA (US); and Board of Regents, The University of Texas System, Austin, TX (US)
Filed by The Scripps Research Institute, La Jolla, CA (US); and Board of Regents, The University of Texas System, Austin, TX (US)
Filed on Jul. 11, 2023, as Appl. No. 18/350,550.
Application 18/350,550 is a division of application No. 15/733,051, granted, now 11,759,461, previously published as PCT/US2018/058190, filed on Oct. 30, 2018.
Claims priority of provisional application 62/578,897, filed on Oct. 30, 2017.
Prior Publication US 2023/0346781 A1, Nov. 2, 2023
Int. Cl. A61K 31/502 (2006.01); A61K 31/437 (2006.01); A61K 31/4704 (2006.01); A61K 31/4741 (2006.01); A61K 31/497 (2006.01); A61K 31/4985 (2006.01); A61K 31/551 (2006.01); A61P 35/00 (2006.01)

CPC A61K 31/502 (2013.01) [A61K 31/437 (2013.01); A61K 31/4704 (2013.01); A61K 31/4741 (2013.01); A61K 31/497 (2013.01); A61K 31/4985 (2013.01); A61K 31/551 (2013.01); A61P 35/00 (2018.01)]

1 Claim

1. A method for treating a patient suffering from a mesenchymally-derived or mesenchymally-transformed cancer, comprising administering to the subject a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof is one selected from the following table:


4A

4B

4C

4D

4E

4

4F

4G

4H

4I

4J

4K

4L

4M